Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans

Abstract

Genetic data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) have been crucial in advancing the understanding of Alzheimer's disease (AD) pathophysiology. Here, we provide an update on sample collection, scientific progress and opportunities, conceptual issues, and future plans.

Document Details

Document Type
Pub Defense Publication
Publication Date
Jul 01, 2015
Source ID
10.1016/j.jalz.2015.05.009

Entities

People

  • Andrew J. Saykin
  • Arthur W. Toga
  • Holly D. Soares
  • John S.k. Kauwe
  • Kelley M. Faber
  • Kwangsik Nho
  • Leanne M. Munsie
  • Michael W. Weiner
  • Nadeem Sarwar
  • Paul M. Thompson
  • Rima Kaddurah‐daouk
  • Robert C. Green
  • Shannon L. Risacher
  • Shen Li
  • Steven G. Potkin
  • Sungeun Kim
  • Tatiana Foroud
  • The Alzheimer’s Disease Neuroimaging Initiative*
  • Vijay K. Ramanan
  • Xiaohui Yao
  • Xiaolan Hu

Organizations

  • Alzheimer's Association
  • Alzheimer's Disease Neuroimaging Initiative
  • Brigham Young University
  • Bristol-Myers Squibb
  • Duke University
  • Eli Lilly and Company
  • Harvard Medical School
  • Indiana University
  • Keck School of Medicine of USC
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute on Aging
  • National Institutes of Health
  • United States Department of Defense
  • University of California, Irvine
  • University of California, San Francisco
  • University of Southern California

Tags

Fields of Study

  • Biology
  • Psychology

Readers

  • Defense Acquisition Program Management
  • Infectious Disease/Epidemiology
  • Neuroscience

Technology Areas

  • Biotechnology